Loading...
By Kristin J. Kelley
Edited by Lorenzo Di Francesco, MD, FACP, FHM
The FDA has approved a label change to varenicline (Chantix) to warn that the smoking cessation drug could "change the way people react to alcohol." Additionally, the label will alert patients to a rare, but possible, risk for seizures.
Varenicline use has been linked to almost 50 adverse events involving alcohol — including decreased tolerance, aggressive behavior, and amnesia — since the drug was approved in 2006, according to data gathered by the FDA. The agency also identified over 60 cases of seizures, most occurring in patients with no seizure history (though some patients may also have been taking other drugs that potentially lower the seizure threshold).
Patients who experience seizures while taking varenicline should stop treatment immediately. The agency also recommends that patients limit their alcohol consumption until they know how they will react to the drug.
In October 2014, an advisory panel voted to keep a black-box warning on varenicline regarding neuropsychiatric adverse events, including suicidal ideation. Results from a Pfizer safety study are expected to be released later this year.
Comment
LINK(S):
FDA MedWatch safety alert (Free)
Background: Physician's First Watch coverage of Chantix black-box warning (Free)